Chinese english Japanese Germany Korea
ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >Proteases >Proteasome inhibitors >Oprozomib

Oprozomib

Oprozomib Structure
CAS No.
935888-69-0
Chemical Name:
Oprozomib
Synonyms
Axelopran;PR 047;CS-696;ONX-0912;OprozoMib;0prozomib;Oprozomib, >=98%;LY335979 ONX-0912;0prozoMib(ONX0912);ONX-0912(Oprozomib)
CBNumber:
CB52628218
Molecular Formula:
C25H32N4O7S
Molecular Weight:
532.61
MOL File:
935888-69-0.mol
MSDS File:
SDS
Modify Date:
2023/5/18 11:31:10
Request For Quotation

Oprozomib Properties

Melting point 147-150°C (dec.)
Boiling point 849.9±65.0 °C(Predicted)
Density 1.290±0.06 g/cm3(Predicted)
storage temp. -20°C Freezer
solubility DMSO (Slightly), Methanol (Slightly)
pka 12.29±0.46(Predicted)
form Solid
color White to Off-White

Oprozomib Chemical Properties,Uses,Production

Description

ONX 0912 is an orally bioavailable proteasome inhibitor. It potently targets the chymotrypsin-like activity of the 20S proteasome subunits β5 and LMP7 (IC50s = 36 and 82 nM, respectively). ONX 0912 inhibits the growth of multiple myeloma cells at nanomolar concentrations while not decreasing the viability of normal peripheral blood mononuclear cells at 1 μM. It blocks the growth of xenografted human multiple myeloma cells in mice when given orally. ONX 0912 has potential applications in certain types of cancer as well as other diseases that require proteasome activity.

Uses

Oprozomib is the second class of proteasome inhibitors with higher specificities and reduced toxicities, against head and neck squamous cell carcinoma.

Enzyme inhibitor

This orally active inhibitor (FW = 532.61 g/mol; CAS 935888-69-0; Solubility: 105 mg/mL DMSO, <1 mg/mL H2O), also known as ONX 0912 and O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)-ethyl]-Lserinamide, selectively targets the chymotrypsin-like (CT-L) activity of 20S proteasome β5 (IC50 = 36 nM) and 20S proteasome LMP7 (IC50 = 82 nM). In animal tumor model studies, ONX 0912 significantly reduced tumor progression and prolonged survival. Immununostaining of multiple myeloma tumors from ONX 0912-treated mice showed growth inhibition, apoptosis, and a decrease in associated angiogenesis. Oprozomib is distinct from carfilzomib, even though the same chemistry was employed to selectively target the proteasome. Oprozomib is under development as an oral therapy for hematologic malignancies, including multiple myeloma, and for patients with recurrent or refractory solid tumors (See also Carfilzomib).

Oprozomib Preparation Products And Raw materials

Raw materials

Preparation Products

Oprozomib Suppliers

Global( 121)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
A.J Chemicals 91-9810153283 New Delhi, India 6124 58 Inquiry
Alpha Biopharmaceuticals Co., Ltd +86-15542445688 China 888 58 Inquiry
ATK CHEMICAL COMPANY LIMITED +undefined-21-51877795 China 32836 60 Inquiry
career henan chemical co +86-0371-86658258 +8613203830695 China 29824 58 Inquiry
Baoji Guokang Bio-Technology Co., Ltd. 0917-3909592 13892490616 China 9316 58 Inquiry
Zhejiang J&C Biological Technology Co.,Limited +1-2135480471 +1-2135480471 China 10522 58 Inquiry
InvivoChem +1-708-310-1919 +1-13798911105 United States 6393 58 Inquiry
LEAP CHEM CO., LTD. +86-852-30606658 China 24738 58 Inquiry
Hangzhou MolCore BioPharmatech Co.,Ltd. +86-057181025280; +8617767106207 China 49739 58 Inquiry
Supplier Advantage
CLEARSYNTH LABS LTD. 58
A.J Chemicals 58
Alpha Biopharmaceuticals Co., Ltd 58
ATK CHEMICAL COMPANY LIMITED 60
career henan chemical co 58
Baoji Guokang Bio-Technology Co., Ltd. 58
Zhejiang J&C Biological Technology Co.,Limited 58
InvivoChem 58
LEAP CHEM CO., LTD. 58
Hangzhou MolCore BioPharmatech Co.,Ltd. 58

Oprozomib Spectrum

Oprozomib(935888-69-0)1HNMR

935888-69-0(Oprozomib)Related Search:

Bortezomib MLN9708 (R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid CEP-18770 MG-132
Carfilzomib
chevron_left

1of2

chevron_right
ONX-0912 OprozoMib OprozoMib (ONX-0912) O-Methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-L-serinamide PR 047 ONX-0912(Oprozomib) OPROZOMIB (ONX 0912);ONX-0912; PR-047 0prozoMib(ONX0912) L-Serinamide, O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl] L-Serinamide, O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]- O-Methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-L-serinamide Oprozomib(ONX-0912) PR 047 0prozomib [(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid Oprozomib, >=98% LY335979 ONX-0912 N-[(2S)-3-methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide OPROZOMIB;ONX-0912;ONX0912;ONX 0912;PR-047;PR047;PR 047 Ortho-Methyl-N-[(2-Methyl-5-Thiazolyl)Carbonyl]- L-Seryl-Ortho-Methyl-N-[(1s)-2-[(2r)-2-Methyl-2- Oxiranyl]-L-Serinamide CS-696 Axelopran ONX-0912 Oprozomib PR-047 N-((S)-3-Methoxy-1-(((S)-3-methoxy-1-(((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide 935888-69-0 C25H32N4O7S Inhibitors Inhibitor